UniQure has started screening patients for its phase 1/2 trial of gene therapy AMT-130 for Huntington’s disease, and says it hopes to start treating the first subject in late 2019 or early 2020.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,